Presentation of Q3 results including outlook

Oncoinvent would like to extend an invitation to a short update on the company and a presentation on Q3 report including outlook. The presentation will be held on Thursday 23. November 2023 at 10:00 AM in the offices of Carnegie, Fjordalléen 16, Oslo, 5. floor, Meeting room: Verftet. It will also be possible to attend virtually.

To attend, please register with ir@oncoinvent.com. Logon details will be distributed to registered attendees.

Oncoinvent ønsker med dette å invitere til en kort status oppdatering og presentasjon av 3. kvartal inkludert veien videre. Presentasjonen vil holdes torsdag 23. november 2023, kl. 10:00 i lokalene til Carnegie, Fjordalléen 16, Oslo, 5. Etasje, Møterom: Verftet Det vil også være mulig å delta virtuelt.

Vi ber om at deltakere registrerer seg ved å sende en e-post til ir@oncoinvent.com. Eventuelle påloggingsdetaljer vil distribueres deretter.

Organiser: Oncoinvent / Carnegie and DnB
Venue:

Carnegie, Fjordalléen 16, Oslo, 5. floor,
Meeting room: Verftet.


Date: 23 November 2023
Program:

About

Management

Board of Directors

Radspherin®

Pipeline

Publications

News

Events

Newsletter subscription

Reports and presentations

Largest shareholders

IR Contact

+47 22 18 33 05

Oncoinvent ASA Gullhaugveien 7 0484 Oslo Norway

© Oncoinvent. All rights reserved. Design by Anagram Design AS

Anders Månsson

Chief Executive Officer

mansson@oncoinvent.com

Anders Månsson is a business executive with over 25 years of experience from management roles in the pharmaceutical industry, focusing on commercialisation and M&A + licensing. Mr. Månsson has held leading roles in the industry both in his native Sweden and in other European countries, and he has worked extensively with the USA and Asia as focus markets in global roles.

Mr. Månsson holds a B.Sc. degree in Business & Economics from Lund’s University in Sweden as well as an MBA from Business School Lausanne in Switzerland. He has a broad-based industrial experience, featuring both large multinational companies such as Meda, Ferring & LEO Pharma, and including leading roles in start-ups and smaller biotech companies. On top of his executive role in Oncoinvent, Mr. Månsson holds two non-executive director positions serving on the board of EQL Pharma AB as well Immetric AB, the latter being an investment company focusing on life science.

close